Australia markets close in 5 hours 33 minutes
  • ALL ORDS

    7,691.10
    +41.80 (+0.55%)
     
  • ASX 200

    7,386.00
    +43.40 (+0.59%)
     
  • AUD/USD

    0.7275
    +0.0013 (+0.19%)
     
  • OIL

    74.80
    +0.82 (+1.11%)
     
  • GOLD

    1,752.70
    +1.00 (+0.06%)
     
  • BTC-AUD

    59,392.49
    +437.96 (+0.74%)
     
  • CMC Crypto 200

    1,075.91
    -27.15 (-2.46%)
     
  • AUD/EUR

    0.6204
    +0.0012 (+0.19%)
     
  • AUD/NZD

    1.0359
    +0.0014 (+0.14%)
     
  • NZX 50

    13,252.66
    -6.89 (-0.05%)
     
  • NASDAQ

    15,329.68
    +13.08 (+0.09%)
     
  • FTSE

    7,051.48
    -26.87 (-0.38%)
     
  • Dow Jones

    34,798.00
    +33.20 (+0.10%)
     
  • DAX

    15,531.75
    -112.25 (-0.72%)
     
  • Hang Seng

    24,192.16
    -318.84 (-1.30%)
     
  • NIKKEI 225

    30,340.29
    +91.48 (+0.30%)
     

Atea Pharmaceuticals to Host Second Quarter Financial Results Conference Call on August 12, 2021

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

BOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Thursday, August 12, 2021 at 4:30 p.m. ET to report financial results for the second quarter ended June 30, 2021, and to provide a clinical and corporate update.

To access the live conference call, please dial (833) 301-1150 (domestic) or (914) 987-7391 (international) at least five minutes prior to the start time, and refer to conference ID 5795073. A live audio webcast of the call and accompanying slide presentation will be available in the Investors’ Events & Presentations section of the Company's website, www.ateapharma.com. An archived webcast will be available on the Atea website approximately two hours after the event.

About Atea Pharmaceuticals

Atea Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing oral therapeutics to address the unmet medical needs of patients with life-threatening viral diseases. Leveraging the Company’s deep understanding of antiviral drug development, nucleos(t)ide chemistry, biology, biochemistry and virology, Atea has built a proprietary nucleotide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of severe viral diseases. Currently, Atea is focused on the development of orally-available, potent, and selective nucleotide prodrugs for difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, dengue virus, hepatitis C virus (HCV) and respiratory syncytial virus (RSV). For more information, please visit www.ateapharma.com.

Contacts

Jonae Barnes
SVP, Investor Relations and Corporate Communications
617-818-2985
Barnes.jonae@ateapharma.com

Will O’Connor
Stern Investor Relations
212-362-1200
will.oconnor@sternir.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting